Burden of Non-Alcoholic Fatty Liver Disease-Related Cirrhosis and Other Chronic Liver Diseases from 1990 to 2019 in China and Disease Burden Trend Prediction to 2030.
Jieyu Peng,Shu Huang,Ping Wang,Rui Luo,Wei Zhang,Xiaomin Shi,Lei Shi,Xiaolin Zhong,Muhan Lü,Yan Peng,Xiaowei Tang
DOI: https://doi.org/10.1097/cm9.0000000000003211
IF: 6.133
2024-01-01
Chinese Medical Journal
Abstract:To the Editor: Nonalcoholic fatty liver disease (NAFLD), a progressive liver disease, is closely related to fat accumulation in the liver. The pathogenesis of NAFLD ranges from hepatic steatosis to more severe steatohepatitis, and then develops into fibrosis and end-stage cirrhosis. The disease has become an independent risk factor for liver-related and all-cause mortality worldwide. With improvements in living standards, NAFLD is the leading chronic liver disease in China. The increasing burden of NAFLD in China has emerged as an important threat to public health, especially its related cirrhosis and other chronic hepatic diseases. A previous study has evaluated the epidemiology, risk factors, complications, and management of NAFLD in China through a systematic review and meta-analysis.[1] Long-term and localized nationwide epidemiological studies on NAFLD and related hepatic complications are rare. The current degree of prevention and control of NAFLD in China and the future development trends are not clear. Therefore, analysis and prediction of the disease burden of NAFLD-related cirrhosis and other chronic diseases in China are necessary. We retrieved data on NAFLD-related cirrhosis and other chronic liver diseases from the Global Burden of Disease Study 2019 Data Resources (GBD 2019). Key disease burden indicators, including incidence, mortality, prevalence, and disability-adjusted life years (DALYs), were analyzed. The age-standardized rate (per 100,000) was calculated based on the age structure of the standard population. Annual percent change (APC), one way to characterize the constant percentage of the changing rate of the disease, and the average annual percent change (AAPC), a summary measure of the trend over a pre-specified fixed interval, were calculated by linear regression analysis of the natural logarithm. Subgroup analysis of sex, age, and socio-demographic index (SDI) was also conducted. The Bayesian age–period–cohort model was used to predict the age-standardized incidence rate (ASIR) and age-standardized mortality rate (ASMR) of the diseases from 2020 to 2030. In 2019, there were 30,644 (95% uncertainty interval [UI]: 18,625–47,682) new cases of NAFLD-related cirrhosis and other chronic liver diseases, causing 14,388 (95% UI: 10,164–19,432) deaths. In total, 293,409,372 (95% UI: 263,682,272–328,429,042) existing cases and 361,859 (95% UI: 245,842–495,974) DALYs were recorded. The ASIR was 1.6 (95% UI: 1.0–2.4) per 100,000 in 2019, with a decrease of −4.4% from 1990. The ASMR and age-standardized DALY rate (ASDR) presented similar decline trends, which decreased from 1.5 (95% UI: 1.0–1.9) per 100,000 to 0.8 (95% UI: 0.5–1.0) per 100,000 and 37.8 (95% UI: 25.8–51.4) per 100,000 to 18.0 (95% UI: 12.6–24.5) per 100,000, with changing rates of −47.5% and −52.2%, respectively. Only the age-standardized prevalence rate (ASPR) exhibited a unique increasing trend with a rate of 15,704.5 (95% UI: 14,041.5–17,575.8) per 100,000 in 2019, accompanied by a fluctuating rate of 25.3%. Females showed a higher ASIR compared to males, whereas males demonstrated performance in ASMR and ASDR. The most significant decline was observed in the ASDR among females with a changing rate of –62.6%, while males experienced the most substantial surge in the ASPR, with a 35.2% increase [Supplementary Table 1 and Supplementary Figure 1, https://links.lww.com/CM9/C72]. At a young age in both 1990 and 2019, the number of cases of four indicators was higher among males than females; however, as the age increased, the trend gradually shifted. The incidence, prevalence, and DALYs rates all exhibited an upward trend initially, followed by a downward trend as age advanced, while the mortality rate continued to rise. Also, middle-aged and older females had a higher incidence rate than males in the same age group. Compared to 1990, the ages of the peak cases of incidence, mortality, and prevalence in 2019 became older, while the ages of DALYs remained stable [Figure 1A–D, Supplementary Figure 2, and Supplementary Tables 2 and 3, https://links.lww.com/CM9/C72].Figure 1: The current and future burden of NAFLD-related cirrhosis and other chronic liver diseases in China. (A) Numbers and rates of incidence stratified by sex and age group in 2019; (B) Numbers and rates of mortality stratified by sex and age group in 2019; (C) Numbers and rates of prevalence stratified by sex and age group in 2019; (D) Numbers and rates of DALYs stratified by sex and age group in 2019; (E) The temporal trends of the ASIR from 1990 to 2019; (F) The temporal trends of the ASMR from 1990 to 2019; (G) Forecasts of the ASRs of incidence in the next ten years among males; (H) Forecasts of the ASRs of incidence in the next ten years among females; (I) Forecasts of the ASRs of mortality in the next ten years among males; (J) Forecasts of the ASRs of mortality in the next ten years among females. ASIR: Age-standardized incidence rate; ASMR: Age-standardized mortality rate; ASRs: Age-standardized rates; DALYs: Disability-adjusted life years; NAFLD: Nonalcoholic fatty liver disease; UIs: Uncertainty intervals. (A–D) Bar chart: number; Line chart: rate. (G–J) Observed rates: dashed lines; Predicted rates: solid lines. The blue region shows the upper and lower limits of the 95% UIs.Significantly changing phases were observed in the ASIR from 1990 to 1994 (APC = −3.202, P <0.05) and from 2011 to 2017 (APC = 2.310, P <0.05). Most decreasing phases were observed in the trends of ASMR, and the significant phases were from 1992 to 1998 (APC = −3.486, P <0.05) and 2004–2011 (APC = −4.438, P <0.05) [Figure 1E, F]. Compared with the global data and the data of five different SDI locations, China had a unique decreasing trend of the ASIR with an AAPC of –0.142 (95% confidence interval [CI]: −0.264 to −0.021) and the most significant decreasing trend of the ASMR with an AAPC of −2.216 (95% CI: −2.374 to −2.059). The changing trend of the ASIR from 1990 to 2019 in China was similar to the global trend, whereas the trends of ASMR were closest to that of the high SDI locations [Supplementary Figure 3 and Supplementary Table 4, https://links.lww.com/CM9/C72]. The ASIR of NAFLD-related cirrhosis and other chronic liver diseases over the next ten years would show an upward trend among both sexes, and the ASMR trend would continue to decrease. From 2019 to 2030, females were predicted to have a higher ASIR and a more significant increasing trend of ASIR, while a higher ASMR and a more significant decline of ASMR were observed among the males [Figure 1G–J]. Characterized by a long course, NAFLD-related cirrhosis and other chronic liver diseases, which can progress to liver cancer, are essentially chronic diseases. During the past 30 years, varied cultures, dietary habits, and socioeconomic conditions greatly affected the burden of the diseases. In our study, a significant increase in the ASPR of the disease was caused by the slight decrease in ASIR and an apparent decrease in ASMR. Although the overall ASIR of NAFLD-related cirrhosis and other chronic liver diseases showed a slightly decreasing trend over the past 30 years, the rate had steadily risen from 2008 to 2019, with a notable increase from 2011 to 2017 (APC = 2.310). Thus, remaining vigilant is important. The ASMR in the five stages experienced varying levels of decline during the six local stages divided by five joinpoints, which can be attributed to wide applications of ultrasound, lifestyle interventions, and pharmacotherapy.[1] Over the past 30 years, the global mortality rate resulting from the disease has been effectively controlled. However, the management of its incidence has varied across different developing countries. China showed comparable patterns of ASIR with the global data, and the ASMR was controlled at the level of high-SDI countries. To some extent, the results indicated good disease control in China during the past 30 years. Notably, the ASIR showed an upward trend over the next ten years, and the ASMR continued to fall. If the trend of increasing ASIR and decreasing ASMR continues, the number and ASPR will balloon, which may cause a heavy disease burden for the country and society. Currently, it is of utmost importance for China to maintain the decreasing ASMR and manage the rising incidence. Differing from the study of Wu et al[2] who reported that the NAFLD incidence was higher in males, we found a female predominance in new cases and ASIR. When further explored the burden stratified by age groups, we observed the middle-aged and older females suffered a higher incidence, which in consistent with the results of Zhai et al,[3] wherein middle-aged female patients were more likely to have nonalcoholic steatohepatitis-related cirrhosis than male patients. The reasons given are that women are more likely to suffer from obesity while consuming less alcohol.[3] Moreover, due to a lack of estrogens, known for their protective functions in lipid metabolism, postmenopausal women have been reported to be more susceptible to metabolic disorders.[4] In 2019, the rates of incidence, prevalence, and DALYs first increased and then decreased with increasing age, while the mortality rate continued to increase. This outcome partially aligned with the findings of Wu et al's study,[2] which reported that the prevalence of NAFLD increased from 8.54% in the 18- to 29-year-old group to 29.14% in the 50- to 59-year-old group, but decreased after 70 years of age. Compared to 1990, the older ages of the peak number may be due to the longer life expectancy and the heavier metabolic disorder burden in older individuals.[5] The development of medical treatment and the one-child policy in China have caused a sharp rise in the elderly population, potentially resulting in a high prevalence of the disease. This study had some limitations. Since the GBD data of NAFLD-related cirrhosis and other chronic liver diseases did not include risk factors, our report lacked relevant analysis. In addition, we could not evaluate the disease burden in the provinces of China due to the unavailable data, while we compared the ASIR and ASMR in China with those in different SDI locations and the global data. Third, GBD 2019 uses statistical modeling and a wide range of data sources including censuses, household surveys, civil registration, vital statistics, disease registries, and other sources to estimate the input data, which might introduce biases. Overall, despite beneficial reductions in incidence, deaths and DALYs due to NAFLD-related cirrhosis and other chronic liver diseases between 1990 and 2019 remain prevalent. Middle-aged and older females may have a severe disease burden. Although the ASMR of the disease is predicted to decrease, the ASIR would increase. Targeted actions and policies are urgently needed to address the NAFLD epidemic in China. Conflicts of interest None